Published 14 November 2008, doi:10.1136/bmj.a2576
Cite this as: BMJ 2008;337:a2576

Editorials

Statins and primary prevention of cardiovascular events

No change in strategy is needed despite the hype surrounding the recent JUPITER study

The first 150 words of the full text of this article appear below.

This week, the New England Journal of Medicine published the randomised controlled trial JUPITER,¹ which compared rosuvastatin (20 mg daily) with placebo in 18 000 patients with no apparent vascular disease, low density lipoprotein cholesterol (LDL-C) of less than 3.4 mmol/l (130 mg/dl), and high sensitivity C reactive protein concentrations of 2.0 mg/l or higher. The combined primary end point was myocardial infarction, stroke, arterial revascularisation, hospital admission for unstable angina, or death from cardiovascular causes. The trial was stopped after a median of two years after a highly significant improvement in the primary end point with rosuvastatin (hazard ratio 0.56; 95% confidence interval 0.46 to 0.69; P<0.00001). It is hardly surprising that the JUPITER study is seen by many as opening the door to new avenues to prevention.

What do the results mean? Do we really have to change our ways of targeting our preventive efforts—for example, measure high . . . [Full text of this article]

¹ Department of General Practice, University of Marburg, D-35032 Marburg, Germany, ² Institute of General Practice, Paracelsus Medical University, A-5020 Salzburg, Austria

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    StumbleUpon    Technorati    What's this?

Relevant Articles

JUPITER may yet change practice

Mikael Rabaeus
BMJ 2008 337: a2921. [Extract] [Full Text]

Strategies for prescribing statins

Norbert Donner-Banzhoff and Andreas Sönnichsen
BMJ 2008 336: 288-289. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Al Badarin, F. J., Kullo, I. J., Kopecky, S. L., Thomas, R. J. (2009). Impact of Ezetimibe on Atherosclerosis: Is the Jury Still Out?. Mayo Clin Proc. 84: 353-361 [Abstract] [Full text]  
• Rabaeus, M. (2008). JUPITER may yet change practice. BMJ 337: a2921-a2921 [Full text]  

Rapid Responses:

Read all Rapid Responses

High level of hs-CRP should be treated with statin irrespective of lipid profile.

Gauranga Dhar
bmj.com, 16 Nov 2008 [Full text]

Maybe JUPITER will change something

Mikael Rabaeus
bmj.com, 16 Nov 2008 [Full text]

Re: Maybe JUPITER will change something

Alexander Jablánczy
bmj.com, 18 Nov 2008 [Full text]

Early Interruption of Jupiter Trial

Ken Leeper
bmj.com, 19 Nov 2008 [Full text]

Three more “fatal myocardial infarctions” in rosuvastatin group than placebo in JUPITER

Malvinder S Parmar
bmj.com, 20 Nov 2008 [Full text]

JUPITER: no cardiovascular deaths prevented

Eddie Vos, et al.
bmj.com, 27 Nov 2008 [Full text]

Online poll

Find out more >>